P4-09-07: Breast Cancer Outcome by Combined Immunohistochemical ER/PR/HER2 Receptor Phenotype
| Autor: | Robert Paridaens, Ignace Vergote, Olivier Brouckaert, Annouschka Laenen, Patrick Berteloot, A Smeets, Patrick Neven, A Reynders, H. Wildiers, Limbergen E Van, P. Moerman, Caroline Weltens, Karin Leunen, Frédéric Amant, M-R Christiaens, Joke Vanderhaegen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pathology medicine.diagnostic_test business.industry Receptor expression Cancer medicine.disease Breast cancer Internal medicine medicine Immunohistochemistry Prospective cohort study business Receptor Survival analysis Fluorescence in situ hybridization |
| Zdroj: | Cancer Research. 71:P4-09 |
| ISSN: | 1538-7445 0008-5472 |
| DOI: | 10.1158/0008-5472.sabcs11-p4-09-07 |
| Popis: | Introduction: We previously reported that molecular prognostic subgroup classification of operable breast cancers resembles the classification based on combined immunohistochemical expression of ER, PR and HER-2 receptors. This update represents a larger cohort with more detailed follow-up (median 5.5y). Patients and methods: A prospective cohort of 4334 breast-cancer patients primary operated at our institution between 2000 and 2009. Steroid receptors were considered positive for any nuclear staining, HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization. Survival curves were calculated for six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP) (figures not allowed in abstract). Disease free interval (DFI), distant metastatis free interval (DMFI), overall survival (OS) and breast cancer specific survival (BCSS) were calculated. A long-rank test was used for testing the null hypothesis of no difference between the groups. Results: Conclusion: Combined receptor expression for ER/PR/HER2 determines specific breast cancer subtypes with significant different clinical behavior. Both predictive and prognostic factors need to be considered when interpreting these results. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-09-07. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|